**Deception Intensiﬁes Stroke Risk in the Elderly**

**BY MITCHEL L. ZOLER**
Philadelphia Bureau

DALLAS — Depression boosted stroke risk in a study of more than 4,000 elderly people followed for 10 years.

People with the highest depression scores at baseline had twice the incidence of a cerebrovascular event or transient ischemic attack during follow-up, compared with people whose depression scores were in the normal range, Dr. Alice S. A. Arjo reported at the annual scientiﬁc sessions of the American Heart Association.

The ﬁnding that depression is a risk factor for stroke follows a prior analysis of the same group of people showing that depression boosted coronary artery disease risk, said Dr. Arjo, director of HeartMasters in Dallas.

The Cardiovascular Health Study Collaborative Research Group enrolled 4,483 men and women aged 65 or older who were completely free of any clinical sign of cardiovascular disease at baseline. The study also excluded patients who were treated with an antidepressant.

All participants were assessed for depression using a modiﬁed version of the Geriatric Depression Scale (GDS). The participants were categorized into quartiles based on their scores. Those with a score of zero had no depression. The next quartile included people with a score of 1–5, followed by quartiles with scores of 6–10, 11–15, and 16 and over.

During 10.3 years of follow-up, 533 people had a stroke, and 1,389 died.

In a multivariate analysis that controlled for baseline differences, the incidence of stroke was related to depression.

Compared with people who had a score of zero, those with a score of 1–5 had 19% more strokes, those with a score of 6–10 had 57% more strokes, those with a score of 11–15 had 78% more strokes, and people with a score of 16–30 had twice as many strokes. The increased stroke rate seen in patients with depression scores of six or higher was signiﬁcantly different from the rate for people with no depression.

An analysis of death rates showed a similar pattern. People with scores of 6–10 had a 27% higher death rate; those with scores of 11–15, 73% higher; and those with scores of 16 or more had 86% more deaths.

Several mechanisms may explain how depression affects stroke rates and mortality, Dr. Arjo said. Depressed people are less physically active and engage in more unsafe behaviors, such as smoking, and increasing scores have increased levels of circulating platelets, ﬁbrinogen, and other factors that raise thrombogenicity.

---

**Duloxetine Beats Placebo at Easing Arthritis Pain, Improving Cognition**

**BY JANE SALOLOF**
MacNeil Southwest Bureau

SANTA ANA PUEBLO, N.M. — Elderly people with depression and arthritis experienced signiﬁcant pain relief with duloxetine in a placebo-controlled trial reported at the annual meeting of the Academy of Psychosomatic Medicine.

Conducted by investigators from Eli Lilly & Co., the research ﬁndings also documented signiﬁcant improvement in cognitive functions, primarily verbal learning and memory, for depressed patients treated with duloxetine (Cymbalta) in the eight-week, multicenter study.

“I think (these ﬁndings are) very encouraging,” investigator Dr. Michael J. Robinson, a clinical research physician at Lilly’s medical division in Indianapolis, said in an interview. “Duloxetine may be advantageous for those speciﬁc cognitive symptoms.”

The results suggest duloxetine can alleviate arthritis pain, a common comorbidity in depressed elderly patients. An in-habitant of serotonin and norepinephrine reuptake, duloxetine is known to have analgesic properties and is approved for treat- ment of peripheral neuropathic pain in patients with diabetes.

Cognition was a primary out- come in the trial, which randomized 207 depressed elderly patients to 60 mg daily of duloxetine and 104 to placebo.

The two cohorts were similar, with an average age of 73 years, slight- ly more women than men, and more than three-fourths the pop- ulation being white. All patients were at least 65 years old and had previous episodes of depression.

Similar proportions of patients withdrew because of adverse events. The most common in the duloxetine group were dry mouth, nausea, and constipation.

Duloxetine produced faster and more signiﬁcant reductions than placebo on the Geriatric Depression Scale (GDS) and the Hamilton Rating Scale for De- pression (HAMD 17). On average, the GDS fell 4.07 in pa- tients on duloxetine vs. 1.34 in the placebo cohort. HAMD 17 scores declined 6.49 with du- lexetine and 3.72 with placebo.

The duloxetine cohort demon- strated signiﬁcantly greater im- provement in a composite score based on four cognitive tests: a mean change of +1.95 vs. +0.76 for the placebo group.

At baseline, the mean com- posite cognitive scores were 22.70 for the duloxetine group and 23.17 for the placebo group. Most of the improvement could be due to changes in scores on verbal learning and recall tests.

Visual analog scale scores for all 311 patients in the trial demonstrated greater improve- ment in back pain and “time in pain while awake” for the du- lexetine cohort. In a subgroup analysis limited to patients with comorbid arthritis, 117 patients on duloxetine had signiﬁcantly greater improvement in four of six pain measures, compared with 51 placebo patient scores.

At the outset, all patients with arthritis had depression scores. All baseline scores on ﬁve of six pain categories assessed with vi- sual analog scales. Overall sever- ity was 38.3 for patients with arthritis vs. 22.5 in patients who did not have arthritis.

Arthritis patients in the du- lexetine cohort had greater im- provements in overall pain, back pain, time in pain while awake, and interference with daily ac- tivities. Arthritis patients in the placebo group had more headache and shoulder pain; the difference was not signiﬁcant.

The mean change in overall pain scores was −6.70 for arthriti- patients on duloxetine vs. −1.89 for arthritis patients on placebo. The most dramatic ef- fect was for back pain, which fell by a mean of more than 20% with duloxetine while increasing more than 10% with placebo.

“We don’t know if this is their pain due to arthritis or their pain due to depression,” Dr. Robinson said. “This is just look- ing at general pain outcomes.”

Baseline scores for depression and improvements in mood were similar for arthritis patients in the two arms of the trial.

In another poster at the meet- ing, a subgroup analysis from seven randomized, multicenter, double-blind trials of duloxetine showed symptom improvement to be similar for white, Hispanic, and African American patients.

Dr. John M. Plewes of Eli Lilly was the principal investigator.

---

**Acetaminophen Improves Social Interaction in Dementia Patients**

**BY MARY ANN MOON**
Contributing Writer

Regular administration of ac- etaminophen raises levels of general activity, social interaction, engagement with media, and worklike activities in elderly patients with moderate to severe dementia, reported John T. Chibnall, Ph.D., of St. Louis University School of Medicine, and his associates.

Regular dosing with the anal- gesic presumably addresses un- treated pain in these patients, who often cannot report pain and who have a high prevalence of comorbid- ities, which can generate sig- niﬁcant pain, the researchers said.

They found their patients’ active engagement with the environment and promotes their withdrawal, Dr. Chibnall, a professor of psychiatry at the uni- versity, and his associates added (Am. Geriatr. Soc. 2005;53:1921-9).

Behavioral changes in 25 elderly (mean age 83 years) nursing home residents with moderate to severe dementia during an 8-week study were evaluated. The subjects had degenerative dementia, Alzheimer’s disease, or multi-in- farct dementia and had resided in nursing homes for a mean of 35 months. All had moderate to se- vere cognitive decline and im- paired in daily living activities.

The subjects were given either acetaminophen or two placebo tablets three times daily every day for 4 weeks, then switched to the other treatment for 4 weeks, following a 1-week washout period between the two phases. Their behavior was evaluated under both condi- tions using the Dementia Care Mapping (DCM) tool, in which trained “mappers” observed pa- tients for 5 hours between 9 a.m. and 2 p.m., when subjects were likely to be most active. At 5-minute intervals, the observers quantiﬁed a wide range of behav- iors across 24 domains such as di- rect or passive social involvement, creative activities, exercise, listen- ing to music, sleeping, and eating.

They also were evaluating using the Cohen-Mansﬁeld Agitation Inventory (MAI), a 29-item scale in which personnel assessed how often the patients displayed a va- riety of agitated behaviors during the preceding 2 weeks.

With acetaminophen, subjects clearly showed higher levels of general activity, spent more time in direct social interactions and in engagement with media, and par- ticipated more in worklike activ- ities. They also spent signiﬁcantly less time alone in their rooms.

However, subjects also spent more time in passive social in- volvement, and slightly more time experiencing unattended distress.

Agitation did not decrease, and the use of psychotropic medica- tions did not decrease, while pa- tients were taking acetaminophen.

However, the levels of agitation and the frequency of agitated be- haviors were quite low in this study, which may have confound- ed the results. Similarly, the use of psychotropic drugs was quite low overall, leaving little room for the intervention to show an effect, the researchers noted.